Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

Soleno Therapeutics (SLNO) Preferred Shares Issued (2016)

Soleno Therapeutics (SLNO) has disclosed Preferred Shares Issued for 2 consecutive years, with $8.4 million as the latest value for Q4 2016.

For Q4 2016, Preferred Shares Issued rose 98.79% year-over-year to $8.4 million; the TTM value through Sep 2017 reached $8.4 million, down 9.58%, while the annual FY2016 figure was $13.5 million, 218.65% up from the prior year.
Preferred Shares Issued hit $8.4 million in Q4 2016 for Soleno Therapeutics, up from -$1000.0 in the prior quarter.
Across five years, Preferred Shares Issued topped out at $8.4 million in Q4 2016 and bottomed at -$1000.0 in Q3 2016.